retatrutide liver benefits for diabetes type 2 Triple hormone receptor agonist metabolic dysfunction-associated steatotic disease: a randomized phase 2a trial Retatrutide is gaining attention in – Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide

A randomized controlled trial using continuous glucose monitoring to guide food choices and diabetes self-care in people with type 2 diabetes not taking insulin

Diabetes Care 2016

Findings GLP-1 receptor agonists and dual incretin agonists exert their therapeutic effects through multiple mechanisms, including enhancement of glucose-dependent insulin secretion, suppression of glucagon release, appetite reduction, and slowing of gastric emptying

PMID 16413237

Monitor how your stomach feels and notice any changes in your energy levels or skin

The incidence in clinical trials was low, but the condition requires prompt recognition and management